JMI LABS IS NOW PART OF LEARN MORE

Filter by Event: Infectious Disease Society of America IDWeek 2019

Resistance to Oral Antibiotics among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017

Resistance to Oral Antibiotics among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017. Lead author: IA Critchley, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1465

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States. Lead author: S Paukner, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 703

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA)

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA). Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #681

Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime-Zidebactam (WCK 5222) Tested against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections

Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime-Zidebactam (WCK 5222) Tested against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1598

Comparison of cefepime-zidebactam (WCK 5222), ceftazidime-avibactam, and ceftolozane-tazobactam tested against Gram-negative organisms causing pneumonia in United States hospitals in 2018

Comparison of cefepime-zidebactam (WCK 5222), ceftazidime-avibactam, and ceftolozane-tazobactam tested against Gram-negative organisms causing pneumonia in United States hospitals in 2018. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2214

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers During 2018

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers During 2018. Lead Author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2217

Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations

Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2192

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018. Lead author: MA Pfaller, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 2115

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1589

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1584

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 1436

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1583

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1445

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018)

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018). Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1582

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017-2018)

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017-2018). Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, D. C., USA
Poster #129

Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas

Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #690

Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods

Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods. Lead author: SJ Ryan Arends, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #701

β-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Isolates Analyzed Using Whole Genome Sequencing (WGS) and Transcriptome Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors

β-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Isolates Analyzed Using Whole Genome Sequencing (WGS) and Transcriptome Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #600

Epidemiologic Analysis of a Worldwide Collection of Escherichia coli ST131 Using the 1928D Core Genome Multilocus Sequence Typing Reveals Country Specific and Globally Disseminated Clades

Epidemiologic Analysis of a Worldwide Collection of Escherichia coli ST131 Using the 1928D Core Genome Multilocus Sequence Typing Reveals Country Specific and Globally Disseminated Clades. Lead author: LM Deshpande, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #239

In vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens Obtained from the United States and Europe from Skin and Skin Structure, Respiratory, and Urinary Tract Infections

In vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens Obtained from the United States and Europe from Skin and Skin Structure, Respiratory, and Urinary Tract Infections. Lead author: MD Huband, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #665

Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacterales (CRE) Isolates

Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacterales (CRE) Isolates. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #677